Cytotoxic t-lymphocyte antigen-4 in colorectal cancer: Another therapeutic side of capecitabine

Derakhshani, A.; Hashemzadeh, S.; Asadzadeh, Z.; Shadbad, M. A.; Rasibonab, F.; Safarpour, H.; Jafarlou, V.; Solimando, A. G.; Racanelli, V.; Singh, P. K.; Najafi, S.; Javadrashid, D.; Brunetti, O.; Silvestris, N.; Baradaran, B.

doi:10.3390/cancers13102414

Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an inhibitory immune checkpoint that can be expressed in tumor-infiltrating lymphocytes and colorectal cancer (CRC) cells. This immune checkpoint can attenuate anti-tumoral immune responses and facilitate tumor growth and metastasis. Although capecitabine is an effective chemotherapeutic agent for treating CRC, its effect on the tumoral CTLA-4 expression remains unclear. In the current research, we applied the GSE110224 and GSE25070 datasets to characterize CTLA-4 expression in CRC patients. Then, we analyzed CTLA-4 expression in CRC samples, HT-29, HCT-166, and SW480 cell lines using real-time PCR. Our bioinformatic results have highlighted the overexpression of CTLA-4 in the CRC tissues compared to the adjacent non-tumoral tissues. Our in vitro studies have indicated that SW480 cells can sub-stantially overexpress CTLA-4 compared to HT-29 and HCT 116 cells. In addition, capecitabine can remarkably downregulate the expression of CTLA-4 in S...

Cytotoxic T lymphocyte antigen-4 (CTLA-4) is an inhibitory immune checkpoint that can be expressed in tumor-infiltrating lymphocytes and colorectal cancer (CRC) cells. This immune checkpoint can attenuate anti-tumoral immune responses and facilitate tumor growth and metastasis. Although capecitabine is an effective chemotherapeutic agent for treating CRC, its effect on the tumoral CTLA-4 expression remains unclear. In the current research, we applied the GSE110224 and GSE25070 datasets to characterize CTLA-4 expression in CRC patients. Then, we analyzed CTLA-4 expression in CRC samples, HT-29, HCT-166, and SW480 cell lines using real-time PCR. Our bioinformatic results have highlighted the overexpression of CTLA-4 in the CRC tissues compared to the adjacent non-tumoral tissues. Our in vitro studies have indicated that SW480 cells can sub-stantially overexpress CTLA-4 compared to HT-29 and HCT 116 cells. In addition, capecitabine can remarkably downregulate the expression of CTLA-4 in SW480 cells. Collectively, capecitabine can inhibit the expression of CTLA-4 in CRC cells and might bridge the immunotherapy approaches with chemotherapy.

Cytotoxic t-lymphocyte antigen-4 in colorectal cancer: Another therapeutic side of capecitabine / Derakhshani, A., Hashemzadeh, S., Asadzadeh, Z., Shadbad, M.A., Rasibonab, F., Safarpour, H., Jafarlou, V., Solimando, A.G., Racanelli, V., Singh, P.K., Najafi, S., Javadrashid, D., Brunetti, O., Silvestris, N., Baradaran, B.. - In: CANCERS. - ISSN 2072-6694. - 13:10(2021), pp. 241401-241411. [10.3390/cancers13102414]